Author

Chiara Greggio

Institution: Bristol-Myers Squibb (Switzerland)

Observed institutions: Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Switzerland)

OpenAlex ID: A5062131998

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

2022 · Saad Usmani, Krina Patel, et al. · Blood · 51

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

2022 · Madhav Dhodapkar, Melissa Alsina, et al. · Blood · 21

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

2023 · Madhav V. Dhodapkar, Melissa Alsina, et al. · Blood · 12

P871: Idecabtagene Vicleucel (ide-cel) in Patients With an Inadequate Response to Frontline Autologous Stem Cell Transplantation (asct): Results From Karmma-2 Cohort 2c

2023 · Melissa Alsina, Madhav Dhodapkar, et al. · HemaSphere · 2

Works count: 4

Citation count: 86

H-index: 3

I10-index: 3